Events|

SHL to participate in Prefilled Syringe Seminar 2018 Tokyo

Press Release 201804 Pda Japan 2018

SHL Group is looking forward to exhibiting at the Prefilled Syringe Seminar 2018 Tokyo held by the Parenteral Drug Association (PDA) Japan Chapter from May 22-23.

The annual seminar will bring together global pharma and medical device experts in an exploration of this year’s theme: the best solution for the patient from the viewpoint of drugs, containers, and devices.

SHL Group will join the event with a showcase of its advanced drug delivery solutions, which include innovative offerings for high volume/high viscosity formulations designed to meet the needs of next-generation therapies.

For the first time in Japan, SHL will be demonstrating Maggie®, a high-volume cartridge-based autoinjector built with the market-proven Needle Isolation Technology (NIT®). SHL will also present its high-volume Molly® 2.25, which offers a shorter development timeline for faster commercialization, and Rotaject®, a state-of-the-art constant force technology that safely delivers viscosities up to several hundred centipoise within seconds.

SHL is pleased to bring its latest portfolio to Japan, a leading market in Asia for self-administered injection devices, and to help biotech and pharma players from around the world to meet their clinical and commercialization needs.

To find out more about SHL’s autoinjection devices and digital solutions, stop by the Sola City Conference Center in Tokyo, Japan from May 22-23.

About SHL

SHL Group is a world-leading solution provider in the design, development and manufacturing of advanced drug delivery devices such as autoinjectors, pen injectors and advanced inhaler systems. We also offer core competencies and services in the fields of medtech and patient care solutions. With locations in Taiwan, Switzerland, Sweden, China and the US, our experienced engineers and designers develop product enhancements as well as breakthrough drug delivery and patient care solutions for pharma and biotech clients globally. Significant investment in R&D has enhanced our broad pipeline of next-generation drug delivery systems that support ongoing innovations in drug development and digital healthcare. This includes advanced reusable and disposable injectors that can accommodate high volume and high viscosities and can be enhanced through digital implementations.

With over 4,800 employees worldwide, SHL Group consists of several distinct group companies:

SHL Medical designs, develops and manufactures advanced drug delivery devices, as well as provides final assembly, labeling and packaging services for leading pharmaceutical and biotech companies across the globe.

SHL Healthcare develops and manufactures equipment solutions for home, hospital and long term care use.

SHL Technologies provides contract manufacturing and engineering services for the production of complex medtech and industrial products.

For additional information, visit www.shl.group

 

Share:

Related News